Related Experiment Video
Updated: Nov 15, 2025

08:20
In Vitro Model of Human Cutaneous Hypertrophic Scarring using Macromolecular Crowding
Published on: May 1, 2020
7.0K
[Expression and effect of microRNA-205 in human hypertrophic scar]
1Department of Burns and Plastic Surgery, General Hospital of Northern Theater Command, Shenyang 110016, China.
Summary
MicroRNA-205 (miR-205) is downregulated in human hypertrophic scars and inhibits fibroblast proliferation by targeting TSP-1. This suggests miR-205 is a potential therapeutic target for hypertrophic scar treatment.
Area of Science:
- Molecular Biology
- Dermatology
- Biochemistry
Background:
- Human hypertrophic scars exhibit altered microRNA expression profiles.
- MicroRNA-205 (miR-205) dysregulation is implicated in various fibrotic conditions.
Purpose of the Study:
- To investigate the role and expression of miR-205 in human hypertrophic scars.
- To determine the effect of miR-205 on fibroblast proliferation and apoptosis.
- To elucidate the relationship between miR-205 and thrombospondin-1 (TSP-1) in hypertrophic scar tissue.
Main Methods:
- Quantitative real-time PCR was used to measure miR-205 and TSP-1 mRNA expression in hypertrophic scar and normal skin tissues.
- Fibroblast cell cultures from hypertrophic scars were transfected with miR-205 mimics or inhibitors.
- Luciferase reporter assays were performed to assess TSP-1 activity.
- Cell viability and apoptosis assays (Hoechst staining) were conducted post-transfection.
Main Results:
- miR-205 expression was significantly lower in hypertrophic scars compared to normal skin.
- TSP-1 mRNA expression was significantly higher in hypertrophic scars.
- Overexpression of miR-205 reduced TSP-1 activity and inhibited fibroblast proliferation.
- Inhibition of miR-205 increased fibroblast proliferation and decreased apoptosis.
Conclusions:
- miR-205 acts as a suppressor of fibroblast proliferation and promotes apoptosis in human hypertrophic scars.
- miR-205 exerts its effects by inhibiting TSP-1 expression.
- miR-205 represents a promising therapeutic target for managing hypertrophic scars.
Related Concept Videos
MicroRNAs
3.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs
23.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.1K
Clinical Applications of Epidermal Stem Cells
3.0K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
3.0K
TGF - β Signaling Pathway
8.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
8.3K

